Charles River Laboratories International (MEX:CRL) Cyclically Adjusted Revenue per Share: MXN1,086.84 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CRL Charles River Laboratories International Inc MEX:CRL
51 GF Score
Price MXN4,720.00
GF Value MXN2,782.12
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Charles River Laboratories International Cyclically Adjusted Revenue per Share?

Charles River Laboratories International MEX:CRL -1.97% 51 Cyclically Adjusted Revenue per Share is MXN1,086.84 as of Jun. 2026. GuruFocus rates MEX:CRL with a GF Score™ of 51/100 and a GF Value™ of MXN2,782.12 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Charles River Laboratories International's adjusted revenue per share for the three months ended in Jun. 2026 was MXN364.844. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN1,086.84 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Charles River Laboratories International's average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Charles River Laboratories International was 16.00% per year. The lowest was 6.30% per year. And the median was 10.20% per year.

As of today (2026-08-16), Charles River Laboratories International's current stock price is MXN4720.00. Charles River Laboratories International's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN1,086.84. Charles River Laboratories International's Cyclically Adjusted PS Ratio of today is 4.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Charles River Laboratories International  (MEX:CRL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Charles River Laboratories International's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4720.00/1086.84
=4.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Charles River Laboratories International Cyclically Adjusted Revenue per Share Related Terms


Charles River Laboratories International Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Cyclically Adjusted Revenue per Share Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1,047.09 978.68 1,434.66 1,169.64

Charles River Laboratories International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,841.95 1,825.25 1,169.64 1,397.30 1,086.84

MEX:CRL vs RVTY, ICLR, QGEN: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Charles River Laboratories International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charles River Laboratories International Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Cyclically Adjusted PS Ratio falls into.


MEX:CRL
51GF Score
Charles River Laboratories International Inc MEX:CRL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charles River Laboratories International Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Charles River Laboratories International's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=364.844/333.9520*333.9520
=364.844

Current CPI (Jun. 2026) = 333.9520.

Charles River Laboratories International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 171.368 241.428 237.042
201612 199.176 241.432 275.503
201703 173.340 243.801 237.436
201706 175.416 244.955 239.148
201709 174.104 246.819 235.567
201712 192.027 246.524 260.128
201803 183.793 249.554 245.951
201806 234.506 251.989 310.782
201809 221.951 252.439 293.619
201812 242.437 251.233 322.260
201903 237.100 254.202 311.485
201906 254.343 256.143 331.605
201909 265.246 256.759 344.991
201912 261.267 256.974 339.531
202003 331.808 258.115 429.297
202006 313.567 257.797 406.197
202009 323.858 260.280 415.526
202012 306.528 260.474 392.998
202103 330.004 264.877 416.063
202106 354.661 271.696 435.927
202109 357.311 274.310 435.000
202112 359.671 278.802 430.818
202203 354.549 287.504 411.829
202206 381.753 296.311 430.248
202209 387.982 296.808 436.536
202212 417.584 296.797 469.860
202303 360.785 301.836 399.173
202306 353.070 305.109 386.447
202309 346.516 307.789 375.971
202312 335.178 306.746 364.906
202403 323.832 312.332 346.248
202406 362.585 314.175 385.409
202409 385.447 315.301 408.247
202412 407.001 315.605 430.661
202503 395.932 319.799 413.454
202506 394.076 322.561 407.992
202509 372.946 324.800 383.455
202512 363.738 324.054 374.848
202603 366.847 330.213 371.001
202606 364.844 333.952 364.844

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN1,086.84 mean?
Charles River Laboratories International (MEX:CRL) has a Cyclically Adjusted Revenue per Share of MXN1,086.84 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Cyclically Adjusted Revenue per Share too high?
Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is MXN1,086.84. Overall, Charles River Laboratories International has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Cyclically Adjusted Revenue per Share compare to RVTY and ICLR?
Charles River Laboratories International's Cyclically Adjusted Revenue per Share of MXN1,086.84 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is MXN1,086.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (MEX:CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,782.12, compared to a current price of MXN4,720.00 — trading 69.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN1,086.84. Charles River Laboratories International's overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Charles River Laboratories International (MEX:CRL), the current Cyclically Adjusted Revenue per Share is MXN1,086.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (MEX:CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of MXN4,720.00 is trading 69.7% above its estimated GF Value™ of MXN2,782.12. GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.

Key valuation signals for MEX:CRL:

  • Cyclically Adjusted Revenue per Share: MXN1,086.84
  • GF Value™: MXN2,782.12 vs. price of MXN4,720.00 (69.7% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the MEX:CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Charles River Laboratories International Business Description

Other Exchanges CRL:USARV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
51GF Score

Get the complete analysis for MEX:CRL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,720.00
Price
MXN2,782.12
GF Value